Pulmonology Practice Questions

Q: A patient comes to you with increased cough, increased breathlessness, and decreased exercise capacity. Chest X-ray shows pulmonary fibrosis. Which drug can be administered in the given condition?

Pirfenidone. ***Pirfenidone***- This drug is an **antifibrotic agent** used specifically in the management of **Idiopathic Pulmonary Fibrosis (IPF)** to slow disease progression and decline in lung function [1].- It works by reducing the synthesis of **Transforming Growth Factor-beta (TGF-$\beta$)** and inhibiting collagen deposition, thus limiting fibrotic remodeling.*Bortezomib*- **Bortezomib** is a **proteasome inhibitor** primarily used in the treatment of hematological malignancies, such as **multiple myeloma** and mantle cell lymphoma.- It has no established role in the pathological treatment or management of the underlying lung fibrosis.*Roflumilast*- **Roflumilast** is a selective **phosphodiesterase-4 (PDE-4) inhibitor** used to reduce the risk of exacerbations in patients with severe **COPD** associated with chronic bronchitis [2].- It is an anti-inflammatory maintenance therapy for COPD, but it is not indicated as an antifibrotic treatment for pulmonary fibrosis [2].*Imatinib*- **Imatinib** is a selective **tyrosine kinase inhibitor** effective against the **BCR-ABL fusion protein**, making it the primary treatment for **Chronic Myeloid Leukemia (CML)**.- While tyrosine kinases are sometimes implicated in fibrosis pathways, Imatinib is not an approved or standard treatment for pulmonary fibrosis.

Q: A 35-year-old woman takes aspirin for a headache, later presented with wheezing and breathlessness. Along with these two symptoms, what other clinical findings are likely to be found in this condition?

Nasal polyp. ***Nasal polyp***- This clinical scenario is classic for **Aspirin-Exacerbated Respiratory Disease (AERD)**, also known as **Samter's Triad**, a condition characterized by three key components.- The three components of Samter's Triad are **asthma** (wheezing/breathlessness), chronic rhinosinusitis with **nasal polyps**, and sensitivity to aspirin/NSAIDs [1].*IgE release*- **Aspirin sensitivity** is a pseudoallergic reaction driven by abnormal metabolism of **arachidonic acid**, specifically involving the COX-1 pathway, and is thus typically **non-IgE mediated**.- This pathway disturbance leads to the overproduction of bronchoconstrictive **leukotrienes** (LTC4, LTD4, LTE4), which are the primary mediators of the reaction.*Extrinsic asthma*- **Extrinsic asthma** refers to allergic asthma, which relies on **IgE-mediated Type I hypersensitivity** reactions triggered by environmental allergens.- AERD is classified as a form of **intrinsic (non-allergic) asthma** because the trigger mechanism is pharmacological/metabolic rather than immunological (allergen-specific IgE) [1].*Drug interaction*- The adverse reaction seen here is an **idiosyncratic drug hypersensitivity reaction** stemming from the patient's underlying disease (AERD), not interaction with another drug.- A true **drug interaction** occurs when one drug alters the absorption, distribution, metabolism, or excretion of another drug, which is irrelevant to leukotriene overproduction.

Q: A 58-year-old male with a 30-year smoking history presents with progressive dyspnea on exertion and dry cough for 8 months. Examination reveals bilateral fine inspiratory crackles at lung bases and digital clubbing. High-resolution CT chest shows bilateral subpleural reticular opacities with honeycombing predominantly in lower lobes. Pulmonary function tests show FEV1/FVC ratio of 0.85 with reduced DLCO. What is the most likely diagnosis?

Idiopathic pulmonary fibrosis. ### Idiopathic pulmonary fibrosis (IPF) - The combination of progressive dyspnea, **digital clubbing**, and bilateral basal **fine inspiratory crackles (Velcro crackles)** is highly suggestive of IPF [1]. - HRCT findings of **subpleural reticular opacities** and **honeycombing** predominantly in the lower lobes represent the definitive usual interstitial pneumonia (**UIP**) pattern [1]. - There is a strong association with cigarette smoking, and the disease typically presents in older adults, often after age 50 [1]. ### Chronic obstructive pulmonary disease (COPD) - COPD is characterized by an **obstructive pattern** on PFTs (FEV1/FVC ratio <0.7), which contradicts the patient's normal ratio of 0.85. - HRCT in COPD primarily shows **centrilobular emphysema** or parenchymal destruction, rather than the severe reticulation and honeycombing described here. ### Hypersensitivity pneumonitis (HP) - Chronic HP often results in fibrosis that preferentially spares the **subpleural region** and typically lacks the classic, profound basal, subpleural **honeycombing** defining UIP [2]. - The typical HRCT findings involve ground-glass opacities, air trapping, and centrilobular nodules, often with a mid-to-upper lung predominance [2]. ### Sarcoidosis - Sarcoidosis most commonly presents with **bilateral hilar lymphadenopathy** and **upper lobe predominant** micronodules or fibrosis. - **Digital clubbing** is rare in sarcoidosis, and the disease pattern usually does not mimic the classic subpleural, basal predominant **UIP/honeycombing** seen here.

Q: A 45-year-old chronic smoker presents with complaints of dyspnea. Pulmonary function tests reveal FEV1/FVC ratio of 65% and RV/ TLC ratio of 141%. Which of the following best describes the underlying pathophysiology?

Air trapping with hyperinflation of lungs. ***Air trapping with hyperinflation of lungs*** - The FEV1/FVC ratio is **65% (below 70%)**, confirming an **obstructive lung disease** (e.g., COPD/emphysema) due to irreversible airflow limitation [2]. - An RV/TLC ratio of **141% (above 120%)** signifies **hyperinflation** (increased **Residual Volume** and **Total Lung Capacity**), which is the direct result of air trapping in the distal airspaces due to airway obstruction [1]. ***Decreased lung compliance*** - Decreased compliance is characteristic of **restrictive lung diseases** (e.g., pulmonary fibrosis), where the lungs are stiff and difficult to inflate. - In obstructive diseases like emphysema, the underlying pathophysiology often involves **destruction of alveolar walls**, which *increases* lung compliance. ***Restrictive lung disease*** - Restrictive diseases are characterized by a **normal or increased FEV1/FVC ratio** and decreased lung volumes (low FVC and TLC), which contradicts the PFT findings (low FEV1/FVC) [3]. - The main physiological problem is difficulty *expanding* the lungs, not difficulty *expelling* air. ***Increased lung compliance*** - While increased compliance is seen in pure emphysema, the PFT findings specifically point to the *consequences* of airway obstruction, which is **air trapping** and subsequent **hyperinflation** (increased RV/TLC ratio) [1]. - Describing the underlying pathophysiology as only 'increased lung compliance' is incomplete, as the most immediate and defining physiological result of severe obstruction leading to dyspnea is the high residual volume due to trapped air.

Q: A patient with a known history of bronchial asthma is currently on salbutamol and ipratropium via MDI. He now presents with nocturnal worsening of symptoms and night time awakening. What is the next best step in management?

Start L.A.B.A + inhaled corticosteroids. ***Start L.A.B.A + inhaled corticosteroids*** - Nocturnal symptoms and night-time awakening indicate persistent or **partially controlled asthma**, necessitating a step-up in therapy (Step 3 or higher treatment based on GINA guidelines) [1]. - The preferred step-up involves adding a daily **low-dose inhaled corticosteroid (ICS)**, often combined with a **Long-Acting Beta Agonist (LABA)**, to address underlying inflammation and provide long-acting bronchodilation [1]. *Increase the dose of salbutamol* - **Salbutamol is a Short-Acting Beta Agonist (SABA)**, used for quick relief (rescue medication), not for controlling chronic inflammation or preventing nocturnal symptoms. - Increasing SABA use without adding anti-inflammatory medication (ICS) is an inappropriate strategy for managing **persistent asthma** and signals poor control. *Add theophylline* - Theophylline is a non-selective phosphodiesterase inhibitor, which is a **less preferred add-on therapy** (Step 4/5) due to its narrow therapeutic index and significant risk of **adverse effects** (e.g., arrhythmias, seizures). - This option is generally reserved for patients who remain symptomatic despite adequate ICS/LABA combination therapy. *Add Montelukast* - Montelukast (a **leukotriene receptor antagonist**) is an optional, less potent add-on therapy typically considered if symptoms persist despite ICS use or if the patient has significant **allergic rhinitis**. - It is **less effective** than adding an ICS-LABA combination when stepping up treatment for poorly controlled persistent asthma.

Q: A patient with COPD presents with progressive dyspnea. ABG shows pH: 7.32, pCO2: 60 mmHg, and HCO3⁻: 32 mEq/L. Which of the following acid-base disorders is present in this patient?

Chronic respiratory acidosis. ***Chronic respiratory acidosis*** - The high **pCO2 (60 mmHg)** indicates primary respiratory acidosis, while the relatively stable pH (**7.32** is mildly acidotic) implies significant renal compensation (elevated **HCO3-**) [1]. - This compensated state, where the pH is buffered despite chronic hypercapnia, is characteristic of a long-standing disease like **COPD** [1], [3]. *Acute respiratory acidosis* - If the acidosis were acute, there would be insufficient time for the kidneys to retain bicarbonate, resulting in a **more severe acidemia** (pH typically <7.25) for a pCO2 of 60 mmHg [2]. - An acute picture is less typical in a patient with stable COPD, which is inherently a **chronic condition** [1]. *Metabolic acidosis* - Metabolic acidosis is defined by a primary reduction in **HCO3-**, leading to a low pH [2]. - In this case, the acidemia is driven by the primary elevation of **pCO2** (hypercapnia), not a decrease in bicarbonate. *Metabolic alkalosis* - This condition is characterized by a primary increase in **HCO3-**, leading to an elevated pH (**alkalemia**). - Since the patient's pH is low (**acidemic**), and the primary driving force is CO2 retention, this diagnosis is incorrect.

Q: Old man underwent joint replacement surgery 3 days ago. Today he develops SOB with chest pain. O/E : pulse 100/min, BP 100/70 mm Hg, RR28/min and sp02: 85% room air. D-dimer is elevated. Which is the next best test

CTPA. ***CTPA*** - This is the **gold standard** for diagnosing acute pulmonary embolism (PE) by visualizing the filling defects in the pulmonary arteries [2]. - Given the high clinical suspicion (post-operative status, classical symptoms, elevated D-dimer) and hemodynamic instability, rapid confirmation with **CTPA** is essential for determining the need for treatments like thrombolysis [2], [3]. *V/Q scan* - **V/Q scans** are generally reserved for patients where CTPA is contraindicated, such as in severe renal failure or certain allergies, and are typically not performed in unstable patients [2]. - It frequently yields an intermediate probability result, which is less conclusive than a CTPA, especially when a definitive, rapid diagnosis is needed due to **hemodynamic compromise**. *ECG* - **ECG** is a vital part of the initial assessment to rule out conditions like acute myocardial infarction and to check for signs of right heart strain common in massive PE (e.g., S1Q3T3 pattern) [1]. - Although crucial for risk stratification, it is only a **supportive test** and is not the definitive diagnostic tool for confirming the presence of PE. *CXR* - The **CXR** is primarily useful for excluding other pulmonary pathologies that mimic PE, such as pneumonia or pneumothorax, and is often normal in the setting of acute PE [1]. - Findings associated with PE (like **Westermark's sign** or **Hampton hump**) are often subtle, non-specific, and lack the sensitivity required to confirm the diagnosis [1].

Q: A patient is on salbutamol and ipratropium but continues to have nocturnal exacerbations of asthma. What is the next step?

Laba plus inhalation steroids. ***Laba plus inhalation steroids*** - In a patient with persistent symptoms (nocturnal exacerbations) despite using a SABA (**salbutamol**) and a SAMA (**ipratropium**), the next step is to initiate or step up therapy by adding a long-term controller medication, which is typically a combination of **Inhaled Corticosteroids (ICS)** and a **Long-Acting Beta-Agonist (LABA)** [1]. - This combination is crucial for controlling airway inflammation and providing prolonged bronchodilation, effectively managing nocturnal symptoms [1], [2]. *Oral corticosteroids* - **Oral corticosteroids** are reserved for acute, severe exacerbations, short courses for bridging, or in cases of very severe asthma refractory to high-dose inhaled therapy [3]. - They are not the standard next step for managing persistent nocturnal symptoms in a patient previously stable on SABA/SAMA. *Montelukast* - **Montelukast** (a leukotriene receptor antagonist) is generally considered a less potent controller than the ICS/LABA combination and is often used as an add-on therapy or for specific phenotypes like aspirin-exacerbated respiratory disease (AERD). - Its efficacy in independently controlling moderate-to-severe persistent asthma, characterized by nocturnal symptoms, is lower than that of ICS/LABA [2]. *Increase the dose of salbutamol* - **Salbutamol** is a **Short-Acting Beta-Agonist (SABA)**, used primarily as a reliever for acute symptoms, not as a long-term controller [2], [4]. - Increasing its dose or frequency significantly suggests reliance on relief medication, which indicates poorly controlled asthma and can increase the risk of adverse cardiac side effects like **tachycardia**.

Q: The following flow volume curve indicates:

Parenchymal obstructive airway disease. ***Parenchymal obstructive airway disease*** - The flow-volume loop shows a **reduced peak expiratory flow** and a **concave slope** of the expiratory limb, characteristic of **airflow obstruction**. - This pattern, particularly with an increased RV and TLC, is typical for conditions like **emphysema** or **chronic bronchitis**, where there is loss of elastic recoil or airway narrowing. *Restrictive defect* - A restrictive defect would typically show a **narrower loop** with reduced lung volumes (TLC, RV), but the shape of the expiratory curve would be more normal or proportionally scaled down, without the prominent concavity. - The primary issue in restrictive diseases is reduced lung compliance, not airway obstruction, so flow rates might be preserved or even increased relative to lung volume. *Extrathoracic obstruction* - Extrathoracic obstruction (e.g., vocal cord dysfunction, goiter compressing the trachea) primarily affects the **inspiratory limb** of the flow-volume loop, causing **flattening of inspiration**. - The expiratory limb in extrathoracic obstruction is typically preserved or much less affected than inspiration. *Intrathoracic obstruction* - **Fixed intrathoracic obstruction** (e.g., tracheal stenosis) causes **flattening of both inspiratory and expiratory limbs**. - A **variable intrathoracic obstruction** (e.g., tracheomalacia) specifically causes **flattening of the expiratory limb** but does not typically result in the marked concavity seen in parenchymal obstructive disease.

Q: Identify the instrument shown below:

Mini-Wright peak flow meter. ***Mini-Wright peak flow meter*** - The image displays a **Mini-Wright peak flow meter**, identifiable by its characteristic tube for blowing into, connected to a plastic casing with a scale - This device is used to measure **Peak Expiratory Flow Rate (PEFR)**, which is crucial for monitoring conditions like **asthma** - The distinctive design with a mouthpiece, moving indicator, and numbered scale is pathognomonic of this device *Spirometer* - A spirometer is a larger device that measures multiple lung volumes and capacities (FVC, FEV1, etc.) - It typically has more complex components including a computerized display or graph paper recorder - Used for comprehensive pulmonary function testing, not just peak flow measurement *Incentive spirometer* - An incentive spirometer is used for post-operative breathing exercises - It has a different design with balls or pistons that rise with inhalation to provide visual feedback - Used for lung expansion therapy, not for measuring PEFR *Wright nebulizer* - A Wright nebulizer is used for administering aerosolized medications - It has a reservoir for liquid medication and produces a fine mist - Not a measurement device but a therapeutic delivery system

Question 1

A patient comes to you with increased cough, increased breathlessness, and decreased exercise capacity. Chest X-ray shows pulmonary fibrosis. Which drug can be administered in the given condition?

Accepted Answer

Pirfenidone

Answer

Imatinib

Answer

Bortezomib

Answer

Roflumilast

Question 2

A 35-year-old woman takes aspirin for a headache, later presented with wheezing and breathlessness. Along with these two symptoms, what other clinical findings are likely to be found in this condition?

Accepted Answer

Nasal polyp

Answer

IgE release

Answer

Extrinsic asthma

Answer

Drug interaction

Question 3

A 58-year-old male with a 30-year smoking history presents with progressive dyspnea on exertion and dry cough for 8 months. Examination reveals bilateral fine inspiratory crackles at lung bases and digital clubbing. High-resolution CT chest shows bilateral subpleural reticular opacities with honeycombing predominantly in lower lobes. Pulmonary function tests show FEV1/FVC ratio of 0.85 with reduced DLCO. What is the most likely diagnosis?

Accepted Answer

Idiopathic pulmonary fibrosis

Answer

Hypersensitivity pneumonitis

Answer

Chronic obstructive pulmonary disease

Answer

Pulmonary tuberculosis

Question 4

A 45-year-old chronic smoker presents with complaints of dyspnea. Pulmonary function tests reveal FEV1/FVC ratio of 65% and RV/ TLC ratio of 141%. Which of the following best describes the underlying pathophysiology?

Accepted Answer

Air trapping with hyperinflation of lungs

Answer

Increased lung compliance

Answer

Restrictive lung disease

Answer

Decreased lung compliance

Question 5

A patient with a known history of bronchial asthma is currently on salbutamol and ipratropium via MDI. He now presents with nocturnal worsening of symptoms and night time awakening. What is the next best step in management?

Accepted Answer

Start L.A.B.A + inhaled corticosteroids

Answer

Add theophylline

Answer

Add Montelukast

Answer

Increase the dose of salbutamol

Question 6

A patient with COPD presents with progressive dyspnea. ABG shows pH: 7.32, pCO2: 60 mmHg, and HCO3⁻: 32 mEq/L. Which of the following acid-base disorders is present in this patient?

Accepted Answer

Chronic respiratory acidosis

Answer

Metabolic acidosis

Answer

Metabolic alkalosis

Answer

Acute respiratory acidosis

Question 7

Old man underwent joint replacement surgery 3 days ago. Today he develops SOB with chest pain. O/E : pulse 100/min, BP 100/70 mm Hg, RR28/min and sp02: 85% room air. D-dimer is elevated. Which is the next best test

Accepted Answer

CTPA

Answer

CXR

Answer

ECG

Answer

V/Q scan

Question 8

A patient is on salbutamol and ipratropium but continues to have nocturnal exacerbations of asthma. What is the next step?

Accepted Answer

Laba plus inhalation steroids

Answer

Montelukast

Answer

Increase the dose of salbutamol

Answer

Oral corticosteroids

Question 9

The following flow volume curve indicates:

Accepted Answer

Parenchymal obstructive airway disease

Answer

Restrictive defect

Answer

Extrathoracic obstruction

Answer

Intrathoracic obstruction

Question 10

Identify the instrument shown below:

Accepted Answer

Mini-Wright peak flow meter

Answer

Spirometer

Answer

Incentive spirometer

Answer

Wright nebulizer

Pulmonology — MCQs

Pulmonology — MCQs

On this page

Practice by Chapter

Want unlimited practice?